en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 339 subscribers, ranking 1 928 in the Medicine category and 5 694 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 339 subscribers.

According to the latest data from 28 June, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 196 over the last 30 days and by -18 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 27.91%. Within the first 24 hours after publication, content typically collects 9.87% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 727 views. Within the first day, a publication typically gains 1 318 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 36.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 29 June, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 339
Subscribers
-1824 hours
+2847 days
+19630 days
Posts Archive
ู…ุฑุญุจุง ุงู†ูŠ ุทุงู„ุจุฉ ุตูŠุฏู„ุฉ ุฌุงู…ุนู‡ ุงู„ู…ุดุฑู‚ ุนู†ุฏูŠ ุจุญุซ ูŠุฎุต ุจุฎุงุฎุงุช ุงู„ุฑุจูˆ ูˆ COPD ู…ู…ูƒู† ุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ูˆ ุงู‡ู…ุดูŠ ุฑู‚ู… collaborator code :3 ูˆ ุดูƒุฑุงู‹ https://forms.gle/hFujpBaFvBNf3kNF6

An intramuscular agent, is approved for second line therapy of postmenopausal patients with hormone receptor-positive breast cancer either alone or in combination with targeted therapy? A) Tamoxifen B) Raloxifene C) Toremifene D) pertuzumab E) Fulvestrant ุจู…ุญุงุถุฑุฉ ุงู„ breast cancer ูู‚ุท ุฏูˆุงุก ูˆุงุญุฏ ู…ุฐูƒูˆุฑ ุงู†ู‡ ู†ู†ุทูŠู‡ im ูŠุนู†ูŠ ุจุฏูˆู† ู…ุง ุชูƒู…ู„ ุงู„ุณุคุงู„ ุชุฎุชุงุฑ ูˆุงู†ุช ู…ุบู…ุถ ูˆูƒู„ุงู… ุงู„ุณุคุงู„ ู†ุตุง ู…ู† ุงู„ู…ู„ุฒู…ุฉ ู…ุงูƒูˆ ู…ุนู„ูˆู…ุฉ ู…ู…ูŠุฒุฉ ู…ุฌุฑุฏ ู…ุนู„ูˆู…ุฉ ุฏุฑุฎูŠุฉ ูˆุฒุงุฑูŠ 25 ุฏูˆุฑ 1 #Breast_Cancer

HER2 over expressing MBC, what is the preferred First line therapy?
Anonymous voting

A patient with HER2-positive MBC was initially treated with a combination of pertuzumab, trastuzumab, and a taxane. After months, her disease progressed. Which of the following treatments is most appropriate as second-line HER2- targeted therapy?
Anonymous voting

ุงู…ุณูƒูŠูˆ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ู…ูˆุงุฏ ุงู„ู†ุธุฑูŠ ุนู„ุงุฌูŠุงุช ุงุฏูุงู†ุณ ุงู‚ุชุตุงุฏูŠุงุช. TDM DDS ุงู„ุจุงูŠูˆุชูƒู†ูˆู„ุฌูŠ ู…/// ู…ู† ู†ู†ุฒู„ ุดูŠ ูŠู†ุถุงู ุน ุงู„ู‚ูˆุงุฆู… ุญุณุจ ูƒู„ ู…ุงุฏุฉ๐Ÿ‘Œ

45-year-old patient with HER2+ breast cancer received neoadjuvant chemotherapy plus trastuzumab and pertuzumab. At surgery, a residual disease was found. Which agent is most appropriate for adjuvant therapy in this condition ?
Anonymous voting

Salma is a 35 years old women presented to gynecologist seeking for strategies for breast cancer prevention because of her positive family history with BRCA 1 and BRCA2 gene test; The best treatment for risk reduction include:
Anonymous voting

Which genetic mutations significantly incrcase the lifetime risk of breast cancer? a- BRCA1 and BRCA2 b- TPS3 and EGFR c- KRAS and NRAS d- ATM and CHEK2 e- BRCA3 and PALB2 ุฏูˆุฑ ุงูˆู„ 2024 ุทุจุนุง ู‡ุงูŠ ุงู„ุงุณุฆู„ุฉ ุชุฎุต ุงูˆู„ ู…ุญุงุถุฑุฉ ู†ุฒู„ุชู‡ุง ุงู„ูƒู… ุงู„ู…ุญุงุถุฑุฉ ุงู„ุฌุงูŠุฉ ุนู„ุงุฌุงุช ุงู„ breast cancer ุณุคุงู„ ุณู‡ู„ ูˆุญุชู‰ ู…ุชู†ุณูˆู† Breast Cancer ู‡ูˆ BR CA #Breast_Cancer

Drug used to prevent Breast cancer. Which drug increased incidence of endometrial cancer a- Exemestane b- anastrozole c- tamoxifen d- raloxifene e- Letrozole ูˆุฒุงุฑูŠ ุฏูˆุฑ ุงูˆู„ 2024 ุงู„ุญู„ ู…ู† ุงู„ุตูˆุฑุฉ ๐Ÿซ† #Breast_Cancer

A 41 years old woman with a positive family history of breast cancer. What is the treatment of choice to reduce her risk breast cancer risk?
Anonymous voting

A 66 years old woman is suffering from low mineral bone density and strong family history of breast cancer. What would be the best protective agent? #Breast_Cancer
Anonymous voting

ุทู„ุงุจ ุงู„ุฎุงู…ุณุฉ ุงู†ุง ุงู† ุดุงุก ุงู„ู„ู‡ ุงูƒู…ู„ ุงู„ูƒุงู†ุณุฑ ูˆุงุจุฏูŠ ุจุงู„ู†ูุณูŠุฉ ู…ู†ุง ู„ุฐุงูƒ ุงู„ูˆู‚ุช ู‡ูˆุงูŠ ุทู„ุงุจ ุชุฑูŠุฏ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ู„ู„ู†ูุณูŠุฉ ู ุงู† ุดุงุก ุงู„ู„ู‡ ุงุซู†ุงุก ุดุฑุญูŠ ู„ู„ูƒุงู†ุณุฑ ุฑุญ ุชู†ุฒู„ ุจู‚ูŠุฉ ุงู„ู…ูˆุงุถูŠุน ุจุดูƒู„ ู…ู„ุงุฒู… ู…ุฑุชุจุฉ ุชุจุงุนุง